FindTrial
Sign In

AI-Driven MRI Tool For Identifying Benign And Malignant Brain Tumors

Integrating artificial intelligence (AI) with MRI for distinguishing Benign and Malignant tumors of Brain. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/03/083745
Enrollment
100
Registered
2025-03-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G988- Other disorders of nervous system Health Condition 2: G988- Other disorders of nervous system

Interventions

Intervention1: nil: nil Control Intervention1: nil: nil

Sponsors

Dr. Pranathi Ravula
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Population Criteria: Patients aged 10 years and above. Individuals with histopathologically confirmed benign or malignant brain tumors. 2. Medical History: Documented clinical history relevant to brain tumor diagnosis and treatment. Patients with no prior surgical, radiation, or chemotherapy intervention to ensure baseline imaging accuracy. 3. MRI Scan Data: High-quality MRI images, including T1-weighted, T2-weighted, and contrast-enhanced sequences. Images free from significant artifacts that could compromise AI analysis.

Exclusion criteria

Exclusion criteria: 1. Population Criteria: Patients below 10 years of age. Patients with non-brain tumors or non-tumor brain conditions (e.g., infections, vascular abnormalities). 2. Medical History: Patients with incomplete or unavailable clinical history. Individuals who have undergone prior surgical, radiation, or chemotherapy interventions before MRI acquisition. Patients with significant comorbidities or contraindications to MRI (e.g., pacemakers, metallic implants). 3. MRI Scan Data: Low-quality MRI images with significant artifacts or incomplete imaging sequences. MRI scans missing critical sequences such as T1-weighted, T2-weighted, or contrast-enhanced images. Imaging data not obtained from standardized MRI protocols.

Design outcomes

Primary

MeasureTime frame
The primary outcome of this study is to accurately identify brain tumors and differentiate between benign and malignant types using AI-enhanced MRI analysis. This involves leveraging AI algorithms trained on diverse MRI sequences to provide precise and reliable classifications that align with histopathological findings, the gold standard for diagnosis.Timepoint: 24 hours—

Secondary

MeasureTime frame
The accuracy of AI-enhanced MRI in differentiating benign from malignant brain tumors, measured against histopathological findings as the gold standard.Timepoint: 30 days—

Countries

India

Contacts

Public ContactPranathi Ravula

Saveetha medical college and hospital

dr.yuvraj1987@gmail.com9840224048

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026